Literature DB >> 18783335

Immunohistochemical evidence of ubiquitous distribution of the metalloendoprotease insulin-degrading enzyme (IDE; insulysin) in human non-malignant tissues and tumor cell lines.

Gregor Weirich1, Karin Mengele, Christina Yfanti, Apostolos Gkazepis, Daniela Hellmann, Anita Welk, Cecylia Giersig, Wen-Liang Kuo, Marsha Rich Rosner, Wei-Jen Tang, Manfred Schmitt.   

Abstract

Immunohistochemical evidence of ubiquitous distribution of the metalloprotease insulin-degrading enzyme (IDE; insulysin) in human non-malignant tissues and tumor cells is presented. Immunohistochemical staining was performed on a multi-organ tissue microarray (pancreas, lung, kidney, central/peripheral nervous system, liver, breast, placenta, myocardium, striated muscle, bone marrow, thymus, and spleen) and on a cell microarray of 31 tumor cell lines of different origin, as well as trophoblast cells and normal blood lymphocytes and granulocytes. IDE protein was expressed in all the tissues assessed and all the tumor cell lines except for Raji and HL-60. Trophoblast cells and granulocytes, but not normal lymphocytes, were also IDE-positive.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18783335      PMCID: PMC3759010          DOI: 10.1515/BC.2008.157

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  30 in total

1.  Functional human insulin-degrading enzyme can be expressed in bacteria.

Authors:  V Chesneau; M R Rosner
Journal:  Protein Expr Purif       Date:  2000-06       Impact factor: 1.650

Review 2.  Tissue microarrays in cancer diagnosis.

Authors:  Ronald Simon; Martina Mirlacher; Guido Sauter
Journal:  Expert Rev Mol Diagn       Date:  2003-07       Impact factor: 5.225

3.  Immunochemical demonstration of immunoreactive insulin in human breast cancer.

Authors:  A Castro; J Ziegels-Weissman; P Buschbaum; W Voigt; A Morales; M Nadji
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1980-07

4.  ATP inhibits insulin-degrading enzyme activity.

Authors:  M C Camberos; A A Pérez; D P Udrisar; M I Wanderley; J C Cresto
Journal:  Exp Biol Med (Maywood)       Date:  2001-04

Review 5.  Insulin clearance in obesity.

Authors:  M Elena Valera Mora; Antonino Scarfone; Menotti Calvani; Aldo V Greco; Geltrude Mingrone
Journal:  J Am Coll Nutr       Date:  2003-12       Impact factor: 3.169

6.  A gene atlas of the mouse and human protein-encoding transcriptomes.

Authors:  Andrew I Su; Tim Wiltshire; Serge Batalov; Hilmar Lapp; Keith A Ching; David Block; Jie Zhang; Richard Soden; Mimi Hayakawa; Gabriel Kreiman; Michael P Cooke; John R Walker; John B Hogenesch
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-09       Impact factor: 11.205

7.  Insulin inhibition of the proteasome is dependent on degradation of insulin by insulin-degrading enzyme.

Authors:  R G Bennett; J Fawcett; M C Kruer; W C Duckworth; F G Hamel
Journal:  J Endocrinol       Date:  2003-06       Impact factor: 4.286

8.  Alternative translation initiation generates a novel isoform of insulin-degrading enzyme targeted to mitochondria.

Authors:  Malcolm A Leissring; Wesley Farris; Xining Wu; Danos C Christodoulou; Marcia C Haigis; Leonard Guarente; Dennis J Selkoe
Journal:  Biochem J       Date:  2004-11-01       Impact factor: 3.857

9.  Regulation of protein degradation by insulin-degrading enzyme: analysis by small interfering RNA-mediated gene silencing.

Authors:  Janet Fawcett; Paska A Permana; Jennifer L Levy; William C Duckworth
Journal:  Arch Biochem Biophys       Date:  2007-09-29       Impact factor: 4.013

10.  Insulin degradation by human skeletal muscle.

Authors:  G W Neal; A E Kitabchi
Journal:  Biochim Biophys Acta       Date:  1982-11-24
View more
  2 in total

1.  Structural changes in intermediate filament networks alter the activity of insulin-degrading enzyme.

Authors:  Ying-Hao Chou; Wen-Liang Kuo; Marsha Rich Rosner; Wei-Jen Tang; Robert D Goldman
Journal:  FASEB J       Date:  2009-07-07       Impact factor: 5.191

Review 2.  Insulin-Degrading Enzyme, an Under-Estimated Potential Target to Treat Cancer?

Authors:  Laetitia Lesire; Florence Leroux; Rebecca Deprez-Poulain; Benoit Deprez
Journal:  Cells       Date:  2022-04-05       Impact factor: 6.600

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.